Featured Research

from universities, journals, and other organizations

Spironolactone did not reduce primary outcome, did reduce hospitalizations for heart failure

Date:
April 9, 2014
Source:
Brigham and Women's Hospital
Summary:
Adding the medication known as spironolactone (Aldactone) to existing therapy did not significantly reduce the composite time to either death from cardiovascular causes, surviving a cardiac arrest, or hospitalization to manage heart failure in patients with heart failure and a preserved ejection fraction, a new study concludes

Findings from the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial, have revealed that adding the medication known as spironolactone (Aldactone) to existing therapy did not significantly reduce the composite time to either death from cardiovascular causes, surviving a cardiac arrest, or hospital­ization to manage heart failure in patients with heart failure and a preserved ejection fraction in a study funded by the National Heart, Lung and Blood Institute, National Institutes of Health.

The study will be published April 10, 2014 in the New England Journal of Medicine.

"There currently are no existing therapies to address the prognoses of the approximately 40 percent of patients with heart failure and a preserved ejection fraction," said Eldrin Lewis, MD, advanced heart failure specialist, Brigham and Women's Hospital (BWH) Division of Cardiovascular Medicine, Department of Medicine, study co-author. "TOPCAT is the first randomized, double-blind trial to assess the effect of a treatment-spironolactone-on clinical outcomes in this patient demographic."

"TOPCAT was robust in its design and was well-conducted, with a strong collaboration between the New England Research Institutes and clinical colleagues at Brigham and Women's Hospital and the University of Michigan, thus ensuring that the results would be reliable," said Sonja McKinlay PhD, president of New England Research Institutes, study co-senior author.

The TOPCAT trial enrolled 3,445 patients from 233 medical sites in six countries. Participants with symptomatic heart failure and a left ventricular ejection fraction of 45 percent or more (normal or near normal contractions) were randomized to receive either spironolactone (15 to 45 milligrams daily) or matching placebo, and were followed for an average of nearly 3.3 years.

The primary outcome consisted of death from cardiovascular causes, surviving a cardiac arrest, or hospitalization for the management of heart failure-whichever happened first-and occurred in 320 of 1,722 patients in the spironolactone group (18.6 percent) and 351 of 1,723 patients in the placebo group (20.4 percent).

Spironolactone belongs to a class of medications known as aldosterone receptor antagonists. Spironolactone is used to treat fluid retention in patients with congestive heart failure, liver cirrhosis or nephrotic syndrome. It is also used to treat high blood pressure, heart failure and low blood potassium (hypokalemia).

Looking at the components of the primary outcome separately, only hospitalizations, specifically for heart failure, had a significantly lower incidence for those taking spironolactone compared to placebo, with 206 patients (12.0 percent) in the spironolactone group undergoing hospitalization versus 245 patients (14.2 percent) in the placebo group.

"While the overall results failed to demonstrate a significant effect of spironolactone on the primary endpoint in TOPCAT, the study provides important insights into the potential efficacy of spironolactone in reducing the need for hospitalizations for heart failure in this population, as well as providing clues for more effectively designing future studies to reduce mortality," said Bertram Pitt, MD, University of Michigan School of Medicine, study co-senior author.

Neither total deaths nor hospitalizations for any reason were significantly reduced by spironolactone. There were no significant differences in the incidence of serious adverse events. However, spironolactone was associated with increased serum creatinine levels and a doubling of the rate of hyperkalemia (high potassium concentration in the blood), but conversely led to reduced hypokalemia (low potassium concentration in the blood). According to the researchers, such findings underscore the importance of monitoring patients prescribed spirono­lactone.

"When treating patients, clinicians must balance risks and benefits," said Marc A. Pfeffer, MD, PhD, BWH Division of Cardiovascular Medicine, Department of Medicine, study co-senior author. "If clinicians decide to prescribe spironolactone to their patients to reduce their risk of being hospitalized for heart failure, there is an associated responsibility to monitor for serum markers of kidney and electrolyte disorders which can be exacerbated by spironolactone."


Story Source:

The above story is based on materials provided by Brigham and Women's Hospital. Note: Materials may be edited for content and length.


Journal Reference:

  1. Bertram Pitt, Marc A. Pfeffer, Susan F. Assmann, Robin Boineau, Inder S. Anand, Brian Claggett, Nadine Clausell, Akshay S. Desai, Rafael Diaz, Jerome L. Fleg, Ivan Gordeev, Brian Harty, John F. Heitner, Christopher T. Kenwood, Eldrin F. Lewis, Eileen O'Meara, Jeffrey L. Probstfield, Tamaz Shaburishvili, Sanjiv J. Shah, Scott D. Solomon, Nancy K. Sweitzer, Song Yang, Sonja M. McKinlay. Spironolactone for Heart Failure with Preserved Ejection Fraction. New England Journal of Medicine, 2014; 370 (15): 1383 DOI: 10.1056/NEJMoa1313731

Cite This Page:

Brigham and Women's Hospital. "Spironolactone did not reduce primary outcome, did reduce hospitalizations for heart failure." ScienceDaily. ScienceDaily, 9 April 2014. <www.sciencedaily.com/releases/2014/04/140409204423.htm>.
Brigham and Women's Hospital. (2014, April 9). Spironolactone did not reduce primary outcome, did reduce hospitalizations for heart failure. ScienceDaily. Retrieved September 23, 2014 from www.sciencedaily.com/releases/2014/04/140409204423.htm
Brigham and Women's Hospital. "Spironolactone did not reduce primary outcome, did reduce hospitalizations for heart failure." ScienceDaily. www.sciencedaily.com/releases/2014/04/140409204423.htm (accessed September 23, 2014).

Share This



More Health & Medicine News

Tuesday, September 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Liberia Pleads for Help to Fight Ebola

Liberia Pleads for Help to Fight Ebola

AP (Sep. 22, 2014) — Liberia's finance minister is urging the international community to quickly follow through on pledges of cash to battle Ebola. Bodies are piling up in the capital Monrovia as the nation awaits more help. (Sept. 22) Video provided by AP
Powered by NewsLook.com
Ebola Doctor Says Border Controls Critical

Ebola Doctor Says Border Controls Critical

AP (Sep. 22, 2014) — A Florida doctor who helped fight the expanding Ebola outbreak in West Africa says the disease can be stopped, but only if nations quickly step up their response and make border control a priority. (Sept. 22) Video provided by AP
Powered by NewsLook.com
Global Ebola Aid Increasing But Critics Say It's Late

Global Ebola Aid Increasing But Critics Say It's Late

Newsy (Sep. 21, 2014) — More than 100 tons of medical supplies were sent to West Africa on Saturday, but aid workers say the global response is still sluggish. Video provided by Newsy
Powered by NewsLook.com
Sierra Leone in Lockdown to Control Ebola

Sierra Leone in Lockdown to Control Ebola

AP (Sep. 21, 2014) — Sierra Leone residents remained in lockdown on Saturday as part of a massive effort to confine millions of people to their homes in a bid to stem the biggest Ebola outbreak in history. (Sept. 20) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins